Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/10—Drugs for disorders of the urinary system of the bladder
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/04—Antipruritics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/12—Radicals substituted by oxygen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
  • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
  • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/62—Oxygen or sulfur atoms
  • C07D213/63—One oxygen atom
  • C07D213/64—One oxygen atom attached in position 2 or 6
  • C07D213/643—2-Phenoxypyridines; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
  • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
  • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D213/72—Nitrogen atoms
  • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/20—Oxygen atoms
  • C07D215/22—Oxygen atoms attached in position 2 or 4
  • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
  • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
  • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D215/38—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
  • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
  • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D231/38—Nitrogen atoms
  • C07D231/40—Acylated on said nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
  • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/30—Oxygen or sulfur atoms
  • C07D233/32—One oxygen atom
  • C07D233/38—One oxygen atom with acyl radicals or hetero atoms directly attached to ring nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
  • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
  • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
  • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D237/20—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
  • C07D239/72—Quinazolines; Hydrogenated quinazolines
  • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
  • C07D239/88—Oxygen atoms
  • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
  • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
  • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
  • C07D241/40—Benzopyrazines
  • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
  • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
  • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
  • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
  • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
  • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
  • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
  • C07D277/62—Benzothiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
  • C07D277/62—Benzothiazoles
  • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
  • C07D277/82—Nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
  • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
  • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
  • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
  • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
  • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
  • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
  • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

• VR1 vanilloid receptor 1
• the vanilloid receptor 1 (VR1) is the molecular target of capsaicin, the active ingredient in hot peppers Julius et al reported the molecular cloning of VR1 (Cate ⁇ na et al., 1997)
• VR1 is a non-selective cation channel which is activated or sensitized by a se ⁇ es of different stimuli including capsaicin and resiniferatoxin (exogenous activators), heat & acid stimulation and products of lipid bilayer metabolism, anandamide (Premkumar et al., 2000, Szabo et al., 2000, Gauldie et al., 2001, Olah et al , 2001) and poxygenase metabolites (Hwang et al., 2000)
• VR1 is highly expressed in primary sensory neurons (Cate ⁇ na et al., 1997) m rats, mice and humans (Onozawa et al., 2000,
• VR1 is also expressed in other neuronal and non-neuronal tissues including but not limited to, CNS nuclei, kidney, stomach and T-cells (Nozawa et al., 2001, Yiangou et al., 2001, Birder et al., 2001). Presumably expression in these va ⁇ ous cells and organs may cont ⁇ bute to their basic properties such as cellular signaling and cell division
• Capsaicin application to the skin in humans causes a painful reaction characte ⁇ zed not only by the perception of heat and pain at the site of administration but also by a wider area of hyperalgesia and allodyma, two characte ⁇ stic symptoms of the human condition of neuropathic pain (Holzer, 1991). Taken together, it seems likely that increased activity of VRl plays a significant role in the establishment and maintenance of pain conditions. Topical or intradermal injection of capsaicin has also been shown to produce localized vasodilation and edema production (Szallasi and Blumberg 1999, Singh et al., 2001).
• VRl agonists or antagonists have use as analgesics for the treatment of pain of various genesis or aetiology, for example acute, inflammatory and neuropathic pain, dental pain and headache, particularly vascular headache such as migraine, cluster headache and mixed vascular syndromes as well as non- vascular, tension headache. They are also useful as anti-inflammatory agents for the treatment of inflammatory diseases or conditions, for example the treatment of arthritis and rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders (e.g. uvetis), inflammatory or unstable bladder disorders (e.g. cystitis and urinary incontinence), psoriasis and skin complaints with inflammatory components, as well as other chronic inflammatory conditions.
• inflammatory diseases or conditions for example the treatment of arthritis and rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders (e.g. uvetis), inflammatory or unstable bladder disorders (e.g. cystitis and urinary incontinence), psori
• neuropathic pain and associated hyperalgesia and allodynia e.g. trigeminal or herpetic neuralgia, diabetic neuropathy pain, causalgia, sympathetically maintained pain and deafferentation syndromes such as brachial plexus avulsion.
• neuropathic pain and associated hyperalgesia and allodynia e.g. trigeminal or herpetic neuralgia, diabetic neuropathy pain, causalgia, sympathetically maintained pain and deafferentation syndromes such as brachial plexus avulsion.
• prophylactic or curative treatment of asthma of epithelial tissue damage or dysfunction, e.g. spontaneous lesions, of herpes simplex, and in the control of disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular e.g.
• Caterina M.J., Schumacher, M.A., Tominaga, M., Rosen, T.A., Levine, J.D., and Julius, D, (1997).
• the capsaicin receptor a heat- activated ion channel in the pain pathway. Nature 389: 816-824.
• Caterina-MJ Leffler-A. Malmberg-AB. Martin-WJ. Trafton-J. Petersen-Zeitz KR. Koltzenburg-M. Basbaum-AI. Julius-D (2000) Impaired nocicepti on and pain sensation in mice lacking the capsaicin receptor. Science-(WASH-DC). 288: 5464: 306-313.
• the present invention comprises a new class of compounds useful in the treatment of diseases, such as vanilloid-receptor-mediated diseases and other maladies, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.
• diseases such as vanilloid-receptor-mediated diseases and other maladies, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.
• the compounds of the invention are useful for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritis, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrot
• the invention also comprises pharmaceutical compositions comprising the compounds, methods for the treatment of vanilloid-receptor-mediated diseases, such as inflammatory or neuropathic pain, asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis diseases, using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of the compounds of the invention.
• vanilloid-receptor-mediated diseases such as inflammatory or neuropathic pain, asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis diseases.
• R 1 , R 2 , R 3 , R 4 , X and Y are defined below.
• One aspect of the current invention relates to compounds having the general structure:
• a naphthyl or saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the naphthyl, heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 ;
• R 2 is H, hydroxy, halo, C ⁇ -6 alkyl substituted by 0, 1 or 2 substituents selected from R 10
• R 3 is H or C 1- alkyl; or R 1 and R 3 together are
• R 5 is independently, at each instance, H, C ⁇ -9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C ⁇ . 4 haloalkyl, -O-C,.
• R 5 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S;
• R 6 is independently, at each instance, H, C ⁇ -9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ]-6 alkyl, -O-C 1-4 haloalkyl, -O-C].
• R 7 is independently, at each instance, H, C 1- alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -OC 1-6 alkyl, -O-C,. 4 haloalkyl, -O-C ⁇ . 6 alkylNR a R a , -O-C,. 6 alkylOR a ,
• R 8 is independently, at each instance, H, C ⁇ -9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C, -6 alkylNR a R a , -O-C ⁇ .
• R 9 is independently, at each instance, H, C ⁇ _ 9 alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -OC 1-6 alkyl, -O-d -4 haloalkyl, -O-d. 6 alkylNR a R a , -O-C ⁇ -6 alkylOR a , -NR a R a , -NR a -C ⁇ -4 haloalkyl, -NR a -C,.
• C ⁇ -4 haloalkyl, halo, nitro, cyano, -OR a , -S( O) n C].
• 6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C ⁇ -6 alkylNR a R ⁇ -O-C ⁇ -6 alkylR c , -O-C ⁇ -6 alkylOR a , -O-C ⁇ -6 alkylC( O)OR a , -NR a R a , -NR a -C ⁇ .
• R 11 is not -O-C 1-6 alkylNR a R a or -O-C 1-6 alkylOR a ;
• R 12 is independently, at each instance, H, C ⁇ _ 9 alkyl, -C ⁇ _ 3 alkylOR a ,
• R 1 is 4-C ⁇ -6 alkylphenyl or 2,4-dimethylphenyl
• R is independently, at each instance, H, phenyl, benzyl or C ⁇ -6 alkyl;
• Y is NH or O; and n is independently, at each instance, 0, 1 or 2; with the proviso that when R 1 is 4-chlorophenyl, then R 4 is not 3-methoxyphenyl.
• R 1 is or a naphthyl or saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the naphthyl, heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 ;
• R 2 is H, hydroxy, halo, C ⁇ _ alkyl substituted by 0, 1 or 2 substituents selected from R 10
• a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 ; and
• R 3 is H or C ⁇ . 4 alkyl.
• R 1 is
• R 7 is independently, at each instance, C 2 . 9 alkyl or C ⁇ _ 4 haloalkyl.
• R 1 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 .
• R is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 .
• R 2 is
• a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 .
• R 2 is
• R 2 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 .
• R 4 is
• Y 2 is -NR a - or -O-.
• R 4 is
• Y 2 is -NR b - or -O-.
• R is
• Y 2 is -NR b - or -O-.
• R 4 is
• Y 2 is -NR b - or -O-.
• R is
• Y 2 is -NR a - or -O-.
• R 4 is
• 4 haloalkyl, -O-C ⁇ -6 alkylNR a R a , -O-C 1-6 alkylOR a , -O-C ⁇ -6 alkylC( O)OR ⁇ -NR a R a , -NR a -C,. 4 haloalkyl, -NR a -C,.
• R 4 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N,
• Another aspect of the invention relates to a compound having the structure:
• n is independently, at each instance, 0, 1 or 2.
• R is a naphthyl substituted by 0, 1, 2 or 3 substituents independently selected from R 5 ; or R 1 is R e substituted by 1, 2 or 3 substituents independently selected from R 5
• R 15 is, independently, in each instance, R 10 , C ⁇ _ 8 alkyl substituted by 0, 1 or
• R substituents selected from R , ⁇ o , -(CH 2 ) n ⁇ henyl substituted by 0, 1, 2 or 3 substituents independently selected from R 10 , or a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 10 ;
• R 16 is, independently, in each instance, H, halo, -NH 2 , -NHC ⁇ -3 alkyl, -N(C ⁇ _ 3 alkyl)C ⁇ . 3 alkyl or C,. 3 alkyl; R 4 is
• R 4 is 10-membered bicyclic ring comprising fused 6-membered rings, containing 0, 1, 2, 3 or 4 N atoms with the remainder being carbon atoms, with at least one of the 6-membered rings being aromatic, wherein the carbon atoms are substituted by H, halo, OR d , NR d R d , C].
• R 5 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S, substituted with 0, 1, 2, or 3 substituents independently selected from R 10 ;
• R 6 is independently, at each instance, H, C ⁇ -5 alkyl, C ⁇ -4 haloalkyl, halo, -OC ⁇ . 6 alkyl, -OC,. 4 haloalkyl, -OC 2-6 alkylNR d R d , -OC 2-6 alkylOR d , -NR d R d , -NR d C ⁇ . 4 haloalkyl, -NR d C 2-6 alkylNR d R d or -NR d C 2-6 alkylOR d , -C ⁇ .
• R 6 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S substituted with 0, 1, 2, or 3 substituents independently selected from R 10 ;
• R 7 is independently, at each instance, H, C ⁇ -8 alkyl, C ⁇ -4 haloalkyl, halo, -OC ⁇ . 6 alkyl, -OC 1 -4 haloalkyl, -OC 2 . 6 alkylNR d R d , -OC 2 . 6 alkylOR d , -NR d R d , -NR d C,. 4 haloalkyl, -NR d C 2 . 6 alkylNR d R d , -NR d C 2-6 alkylOR d , -C ⁇ _ 8 alkylOR d , -C, -6 alkylNR d R or -S(C ⁇ .
• R 7 is a saturated or unsaturated 4- or 5-membered ring heterocycle containing a single nitrogen atom, wherein the ring is substituted with 0, 1 or 2 substituents independently selected from halo, C ⁇ . 2 haloalkyl and C ⁇ -3 alkyl;
• R 8 is independently, at each instance, H, d. 5 alkyl, C ⁇ - 4 haloalkyl, halo,
• R 6 alkyl a phenyl ring substituted with 1, 2, or 3 substituents independently selected from R 10
• R 8 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S substituted with 0, 1, 2, or 3 substituents independently selected from R 10 ;
• R 9 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S substituted with 0, 1, 2, or 3 substituents independently selected from R 10 ; or R 9 is a saturated or unsaturated 4- or 5-membered ring heterocycle containing a single nitrogen atom, wherein the ring is substituted with 0, 1 or 2 substituents independently selected from halo, C ⁇ -2 haloalkyl and C ⁇ _ 3 alkyl; wherein at least one of R , R , R , R 8 and R 9 is C ⁇ .
• R 10 is a saturated or unsaturated 5-, 6- or 7-membered monocyclic or 6-, 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 1, 2 or 3 atoms selected from N, O and S, wherein the ring is fused with 0 or 1 benzo groups and 0 or 1 saturated or unsaturated 5-, 6- or 7-membered heterocyclic ring containing 1, 2 or 3 atoms selected from N, O and S; wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 groups selected from C ⁇ -8 alkyl, C ]-4 haloalkyl, halo, cyano,
• R is independently, at each instance, selected from H, C ⁇ -8 alkyl
• R 12 is a saturated or unsaturated 5-, 6- or 7-membered monocyclic or 6-, 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 1, 2 or 3 atoms selected from N, O and S, wherein the ring is fused with 0 or 1 benzo groups and 0 or 1 saturated or unsaturated 5-, 6- or 7-membered heterocyclic ring containing 1, 2 or 3 atoms selected from N, O and S; wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 groups selected from C ⁇ - 8 alkyl, C ⁇ -4 haloalkyl, halo, cyano,
• R 13 is independently, at each instance, selected from H, d. 8 alkyl,
• R 13 is a saturated or unsaturated 5-, 6- or 7-membered monocyclic or 6-, 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 1, 2 or 3 atoms selected from N, O and S, wherein the ring is fused with 0 or 1 benzo groups and 0 or 1 saturated or unsaturated 5-, 6- or 7-membered heterocyclic ring containing 1, 2 or 3 atoms selected from N, O and S; wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 groups selected from C ⁇ . 8 alkyl, C ⁇ _ 4 haloalkyl, halo, cyano, nitro,
• R 14 is a saturated or unsaturated 5-, 6- or 7-membered monocyclic or 6-, 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 1, 2 or 3 atoms selected from N, O and S, wherein the ring is fused with 0 or 1 benzo groups and 0 or 1 saturated or unsaturated 5-, 6- or 7-membered heterocyclic ring containing 1, 2 or 3 atoms selected from N, O and S;
• R d is independently, at each instance, H, phenyl, benzyl or C 1-6 alkyl;
• R e is a heterocycle selected from the group of thiophene, pyrrole, 1,3-oxazole, 1,3-thiazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, lH-l,2,3-triazole, isothiazole, 1,2,4-oxadiazole, 1,2,4- thiadiazole, 1,2,3,4-oxatriazole, 1,2,3,4-thiatriazole, lH-l,2,3,4-tetraazole, 1,2,3,5-oxatriazole, 1,2,3,5-thiatriazole, furan, imidazol-1-yl, imidazol-4-yl, 1,2,4- triazol-4-yl, l,2,4-triazol-5-y
• heterocycle is optionally vicinally fused with a saturated or unsaturated 5-, 6- or 7-membered ring containing 0, 1 or 2 atoms independently selected from N, O and S;
• R f is phenyl substituted by 0, 1 or 2 groups selected from halo, C 1-4 alkyl, C ⁇ -3 haloalkyl, -OR d and -NR d R d ; or R f is a saturated or unsaturated 5- or
• 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the carbon atoms of the heterocycle are substituted by 0, 1 or 2 oxo groups, wherein the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents selected from halo, C ⁇ -4 alkyl, C,. 3 haloalkyl, -OR d and -NR d R d ; and
• R is hydrogen or -CH 3 .
• R 16 is halo, -NH 2 , -NHC ⁇ _ 3 alkyl, -N(C ⁇ _ 3 alkyl)C,. 3 alkyl or C,. 3 alkyl.
• R 10 is C alkyl substituted by 0, 1, 2 or 3 groups selected from d.
• R 1 is
• R 7 is C ⁇ -5 alkyl, halo or C ⁇ _ 4 haloalkyl.
• R 1 is naphthyl substituted by 0, 1, 2 or 3 substituents independently selected from R 5 .
• R 1 is R e substituted by 0, 1, 2 or 3 substituents independently selected from R 5 . In another embodiment, in conjunction with the novel compound embodiments above and below, R 1 is R e substituted by 1, 2 or 3 substituents independently selected from R 5 .
• R 4 is
• Another aspect of the invention relates to a compound having the structure:
• R 1 is a naphthyl substituted by 0, 1, 2 or 3 substituents independently selected from R 5 ; or R 1 is R e substituted by 1, 2 or 3 substituents independently selected from R 5 ;
• R 15 is, independently, in each instance, R 10 , C ⁇ -8 alkyl substituted by 0, 1 or
• R 10 substituents selected from R 10 , -(CH 2 ) n phenyl substituted by 0, 1, 2 or 3 substituents independently selected from R 10 , or a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 10 ;
• R 16 is, independently, in each instance, H, halo, -NH 2 , -NHCi_ alkyl, -N(C, -3 alkyl)C ⁇ . 3 alkyl or C ⁇ . 3 alkyl;
• R 4 is a saturated or unsaturated 5- or 6-membered ring containing 0, 1, 2 or
• R 5 is independently, at each instance, H, C ⁇ _ alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC 1-6 alkyl, -OC haloalkyl, -OC 2-6 alkylNR d R d , -OC 2-6 alkylOR d , -NR d R d , -NR d C, -4 haloalkyl, -NR d C 2 .
• R is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S, substituted with 0, 1, 2, or 3 substituents independently selected from R ;
• R 6 is independently, at each instance, H, C ⁇ _ 5 alkyl, C ⁇ - haloalkyl, halo, -OC 1-6 alkyl, -OC 1-4 haloalkyl, -OC 2 - 6 alkylNR d R d , -OC 2 .
• R 6 alkyl
• R 6 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S substituted with 0, 1, 2, or 3 substituents independently selected from R 10 ;
• R 7 is independently, at each instance, H, C ⁇ _ 8 alkyl, C 1- haloalkyl, halo, -OC ⁇ _ 6 alkyl, -OC 1-4 haloalkyl, -OC 2-6 alkylNR d R d , -OC 2-6 alkylOR d , -NR d R d , -NR d C 1 -4 haloalkyl, -NR d C 2-6 alkylNR d R d , -NR d C 2-6 alkylOR d , -C,.
• alkylOR d -C ⁇ . 6 alkylNR d R d or -S(C ⁇ _ 6 alkyl); or R 7 is a saturated or unsaturated 4- or 5-membered ring heterocycle containing a single nitrogen atom, wherein the ring is substituted with 0, 1 or 2 substituents independently selected from halo, C ⁇ . 2 haloalkyl and C]. alkyl;
• R 8 is independently, at each instance, H, C ⁇ -5 alkyl, C ⁇ -4 haloalkyl, halo, -OC ⁇ -6 alkyl, -OC 1-4 haloalkyl, -OC 2-6 alkylNR d R d , -OC 2 . 6 alkylOR d , -NR d R d , -NR d C 1-4 haloalkyl, -NR d C 2 . 6 alkylNR d R d , -NR d C 2 . 6 alkylOR d , -C,.
• R 8 alkylOR d , -C )-6 alkylNR d R d , -S(C 1-6 alkyl), a phenyl ring substituted with 1, 2, or 3 substituents independently selected from R 10 , or R 8 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S substituted with 0, 1, 2, or 3 substituents independently selected from R 10 ; R 9 is independently, at each instance, H, C ⁇ _ alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -OC haloalkyl, -OC 2 - 6 alkylNR d R d ,
• R 10 is independently, at each instance, selected from H, C ⁇ -8 alkyl,
• R 10 is a saturated or unsaturated 5-, 6- or 7-membered monocyclic or 6-, 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 1, 2 or 3 atoms selected from N, O and S, wherein the ring is fused with 0 or 1 benzo groups and 0 or 1 saturated or unsaturated 5-, 6- or 7-membered heterocyclic ring containing 1, 2 or 3 atoms selected from N, O and S; wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 groups selected from C ⁇ . 8 alkyl, d. 4 haloalkyl, halo, cyano,
• R d is independently, at each instance, H, phenyl, benzyl or C ⁇ -6 alkyl;
• R e is a heterocycle selected from the group of thiophene, pyrrole, 1,3-oxazole, 1,3-thiazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, lH-l,2,3-triazole, isothiazole, 1,2,4-oxadiazole, 1,2,4- thiadiazole, 1,2,3,4-oxatriazole, 1,2,3,4-thiatriazole, lH-l,2,3,4-tetraazole,
• R f is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the carbon atoms of the heterocycle are substituted by 0, 1 or 2 oxo groups, wherein the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents selected from halo, C 1 -4 alkyl, C 1-3 haloalkyl, -OR d and -NR d R d ;
• R g is hydrogen or -CH 3 ;
• R m is independently at each instance H or R n ;
• R n is independently at each instance C ⁇ _ 8 alkyl, phenyl or benzyl;
• R s is R n substituted by 0, 1, 2 or 3 substituents independently selected from R q .
• Y is NH
• Y is O.
• Y is S.
• R 1 is
• R 7 is C ⁇ _ 5 alkyl, halo or C]. 4 haloalkyl.
• R 1 is a naphthyl substituted by 0, 1, 2 or 3 substituents independently selected from R 5 .
• R 1 is R e substituted by 1, 2 or 3 substituents independently selected from R 5 ;
• R 15 is -(CH 2 ) n ⁇ henyl substituted by 0, 1, 2 or 3 substituents independently selected from R 10 .
• R 15 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 10 .
• R 15 is C ⁇ _ 8 alkyl substituted by 0, 1 or 2 substituents selected from R 10 .
• R 16 is, independently, in each instance, halo
• R is a saturated or unsaturated 5- or 6-membered ring containing 1, 2 or 3 atoms selected from O, N and S that is vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from C ⁇ .
• R 9 is H.
• R 9 is independently, at each instance, C ⁇ -8 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ _ 6 alkyl, -OC ⁇ - haloalkyl, -OC 2-6 alkylNR d R d , -OC 2 . 6 alkylOR d , -NR d R d , -NR d C,. 4 haloalkyl, -NR d C 2 . 6 alkylNR d R d or -NR d C 2 . 6 alkylOR d , -CO 2 (C ⁇ .
• R 9 is a -(CR q R q ) 0 phenyl wherein the phenyl is substituted with 0, 1, 2, or 3 substituents independently selected from R 10 .
• R 9 is -(CR q R q ) o Het wherein Het is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S substituted with 0, 1, 2, or 3 substituents independently selected from R 10 ; or R 9 is a saturated or unsaturated 4- or 5-membered ring heterocycle containing a single nitrogen atom, wherein the ring is substituted with 0, 1 or 2 substituents independently selected from halo, C ⁇ -2 haloalkyl and C ⁇ -3 alkyl.
• Another aspect of the invention relates to a compound having the structure: or any pharmaceutically-acceptable salt thereof, wherein: Y is O or S; n is independently, at each instance, 0, 1 or 2.
• R 1 is a naphthyl substituted by 0, 1, 2 or 3 substituents independently selected from R 5 ; or R 1 is R 1 substituted by 1, 2 or 3 substituents independently selected from R 5 ; R 15 is, independently, in each instance, R 10 , C ⁇ _ 8 alkyl substituted by 0, 1 or
• R 10 substituents selected from R 10 , -(CH 2 ) classroomphenyl substituted by 0, 1, 2 or 3 substituents independently selected from R 10 , or a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S that is optionally vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, the heterocycle and bridge being substituted by 0, 1, 2 or 3 substituents independently selected from R 10 ;
• R 16 is, independently, in each instance, H, halo, -NH 2 , -NHC ⁇ -3 alkyl, -N(C ⁇ . 3 alkyl)C ⁇ -3 alkyl, -OC 1-3 alkyl, -C ⁇ -2 haloalkyl, -OC 1-2 haloalkyl or C, -3 alkyl; R 4 ⁇ s
• R 5 is independently, at each instance, H, C ⁇ -5 alkyl, C ⁇ -4 haloalkyl, halo, nitro, -OC ]-6 alkyl, -OC,. 4 haloalkyl, -OC 2 .
• R 5 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S, substituted with 0, 1, 2, or 3 substituents independently selected from R 10 ;
• R 6 is independently, at each instance, H, C ⁇ -5 alkyl, C]. 4 haloalkyl, halo, -OC I-6 alkyl, -OC ⁇ -4 haloalkyl, -OC 2 . 6 alkylNR h R h , -OC 2 . 6 alkylOR h , -NR h R h , -NR h C ⁇ -4 haloalkyl, -NR h C 2-6 alkylNR h R h or -NR h C 2 - 6 alkylOR h , -C ⁇ -8 alkylOR h , -C ⁇ .
• R 7 is independently, at each instance, H, C ⁇ -8 alkyl, C 1-4 haloalkyl, bromo, -OC, -6 alkyl, -OC ]-4 haloalkyl, -OC 2-6 alkylNR h R h , -OC 2-6 alkylOR h , -NR h R h , -NR h C ⁇ . 4 haloalkyl, -NR h C 2-6 alkylNR h R h , -NR h C 2 . 6 alkylOR h , -C ⁇ - 8 alkylOR h , -C, -6 alkylNR h R h or -S(C,.
• R 7 is a saturated or unsaturated 4- or 5-membered ring heterocycle containing a single nitrogen atom, wherein the ring is substituted with 0, 1 or 2 substituents independently selected from halo, d -2 haloalkyl and C 1-3 alkyl;
• R 8 is independently, at each instance, H, C ⁇ -5 alkyl, C ]-4 haloalkyl, halo,
• R 6 alkyl a phenyl ring substituted with 1, 2, or 3 substituents independently selected from R 10
• R 8 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 atoms selected from O, N and S substituted with 0, 1, 2, or 3 substituents independently selected from R 10
• R 9 is independently, at each instance, H, d. 8 alkyl, C ⁇ -4 haloalkyl, halo, nitro, -OC,. 6 alkyl, -OC ⁇ -4 haloalkyl, -OC 2 .
• R 9 is a saturated or unsaturated 4- or 5-membered ring heterocycle containing a single nitrogen atom, wherein the ring is substituted with 0, 1 or 2 substituents independently selected from halo, C ⁇ -2 haloalkyl and C ⁇ -3 alkyl;
• R 13 is a saturated or unsaturated 5-, 6- or 7-membered monocyclic or 6-, 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 1, 2 or 3 atoms selected from N, O and S, wherein the ring is fused with 0 or 1 benzo groups and 0 or 1 saturated or unsaturated 5-, 6- or 7-membered heterocyclic ring containing 1, 2 or 3 atoms selected from N, O and S; wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 groups selected from C ⁇ -8 alky
• R h is independently, at each instance, H, phenyl, benzyl or C ⁇ -6 alkyl, the phenyl, benzyl and C ⁇ . 6 alkyl being substituted by 0, 1, 2 or 3 substituents selected from halo, C alkyl, C,.
• R 1 is a heterocycle selected from the group of thiophene, pyrrole, 1,3- oxazole, l,3-thiazol-5-yl, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,3-oxadiazole, 1,2,3-thiadiazole, lH-l,2,3-triazole, isothiazole, 1,2,4-oxadiazole, 1,2,4- thiadiazole, 1,2,3,4-oxatriazole, 1,2,3,4-thiatriazole, lH-l,2,3,4-tetraazole, 1,2,3,5-oxatriazole, 1,2,3,5-thiatriazole, furan, imidazol-1-yl, imidazol-3-yl, imi
• R j is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the carbon atoms of the heterocycle are substituted by 0, 1 or 2 oxo groups, wherein the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents selected from halo, C alkyl, C 1-3 haloalkyl, -OR h and -NR h R h ; and
• R k is hydrogen or -CH 3 .
• R 1 is
• R 7 is C 2-6 alkyl or C ⁇ . 4 haloalkyl.
• R 1 is a naphthyl substituted by 0, 1, 2 or 3 substituents independently selected from R 5 .
• R 1 is R l substituted by 1, 2 or 3 substituents independently selected from R 5 .
• R' is substituted by one substituent selected from halo, C ⁇ _ 4 haloalkyl and C ⁇ _ 5 alkyl, and additionally by 0, 1 or 2 substituents independently selected from R 5 .
• R 15 is H.
• R 15 is R 10 , C ⁇ -8 alkyl substituted by 0, 1 or 2 substituents selected from R 10 , or a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S that is optionally vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, the heterocycle and bridge being substituted by 0, 1, 2 or 3 substituents independently selected from R 10 ; or R 15 is -(CH 2 ) n phenyl substituted by 0, 1, 2 or 3 substituents independently selected from H, C ⁇ -8 alkyl,
• R 16 is H
• R 16 is halo, -NHC ⁇ -3 alkyl, -N(C ⁇ _ 3 alkyl)C ⁇ _ 3 alkyl, -OC ⁇ -3 alkyl, -C ⁇ -2 haloalkyl, -OC ⁇ -2 haloalkyl or C ⁇ -3 alkyl.
• R 4 is
• R 10 , R 11 , R 12 , R 13 and R 14 is other than C ⁇ . 4 haloalkyl or halo.
• R 10 , R 11 , R 12 , R 13 and R 14 is -OR h or -NR h R h .
• R 4 is a saturated or unsaturated 5- or 6-membered ⁇ ng heterocycle containing 1 or 2 atoms selected from O, N and S, wherein each of the carbon atoms of the heterocycle is substituted by H, Cj.
• R 6 and R are each independently selected from H, C ⁇ -5 alkyl, C haloalkyl, halo, -OC ⁇ . 6 alkyl, -OC ⁇ -4 haloalkyl, -OC 2 . 6 alkylNR h R h , -OC 2-6 alkylOR h , -NR h R h , -NR h C,. 4 haloalkyl, -NR h C 2-6 alkylNR h R h or -NR h C 2-6 alkylOR h , -C,. 8 alkylOR h , -C ⁇ . 6 alkylNR h R h and -S(d -6 alkyl).
• R 7 is independently, at each instance, C,. 8 alkyl, d. 4 haloalkyl, -OC, -4 haloalkyl, -OC 2 . 6 alkylNR h R h , -OC 2-6 alkylOR h , -NR h R h , -NR h C,. 4 haloalkyl, -NR h C 2-6 alkylNR h R h , -NR h C 2-6 alkylOR h , -C ⁇ _ 8 alkylOR h , -C ⁇ . 6 alkylNR h R h or -S(C,. 6 alkyl).
• Y is O.
• Y is S.
• Another aspect of the invention relates to a compound having the structure:
• X is O, S or NR m ; n is independently, at each instance, 0, 1 or 2; o is independently, at each instance, 0, 1, 2 or 3;
• R m is independently at each instance H or R n ;
• R n is independently at each instance C ⁇ -8 alkyl, phenyl or benzyl;
• R s is R n substituted by 0, 1, 2 or 3 substituents independently selected from R q ;
• R 3 is H or C ⁇ . 4 alkyl
• R 5 is H, C ⁇ . 9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ _ 6 alkyl,
• R 6 is, independently at each instance, H, C). 9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C haloalkyl, -O-C ⁇ . 6 alkylNR m R m , -O-C,. 6 alkylOR m , -NR m R m , -NR m -C, ⁇ haloalkyl, -NR m -C,. 6 alkylNR m R m or -NR m -C, -6 alkylOR m ;
• R 8 is H, C ⁇ -9 alkyl, C ⁇ . 4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C 1-4 haloalkyl, -O-C 1-6 alkylNR m R m , -O-d_ 6 alkylOR m , -NR m R m , -NR m -C 1-4 haloalkyl, -NR m -C ⁇ . 6 alkylNR m R m or -NR m -C ⁇ _ 6 alkylOR m ; and (A) R 1 is
• R 2 is H, -OR m , halo, C 1-3 haloalkyl or C,. 6 alkyl;
• R 7 is C ⁇ . 9 alkyl, C ⁇ - haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl,
• -O-C ⁇ -4 haloalkyl, -O-C ⁇ -6 alkylNR m R m , -O-C,. 6 alkylOR m , -NR m R m , -NR m -C,. 4 haloalkyl, -NR m -C 1-6 alkylNR m R m or -NR m -C, -6 alkylOR m ;
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic or 1-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 2, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p ;
• R 2 is H, -OR m , halo, Cuhaloalkyl or C,. 6 alkyl;
• R >4 i •s a saturated or unsaturated 5- or 6-membered ring containing 0, 1, 2 or 3 atoms selected from O, N and S that is optionally vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from C ⁇ _ 8 alkyl, C,.
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 2, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p ;
• Y is O or NH; or (C) R 1 is R 2 is H, -OR m , halo, C, -3 haloalkyl or C ⁇ -6 alkyl;
• R 4 is a saturated, partially-saturated or unsaturated 8-, 9-, 10 or
• R 4 is not 2-aminocarbonylmethyl-2,3-dihydro-benzo[l,4]dioxin-8-yl, 2-cyanomethyl- 2,3-dihydro-benzo[l,4]dioxin-8-yl, quinolin-3-yl, 3H-quinazolin-4-on-3-yl, benzo[l,3]dioxol-5-yl, 3,3-dimethyl-l,3-dihydro-indol-2-on-6-yl or 4,4-dimethyl- 3,4-dihydro-lH-quinolin-2-on-7-yl;
• R 7 is C ⁇ . 8 alkyl, C ]-5 haloalkyl, I or Br R 9 is H, C ⁇ -9 alkyl, d. 4 haloalkyl, halo, nitro, cyano, -O-C ⁇ -4 haloalkyl, -O-C ⁇ -6 alkylNR m R m , -O-C ⁇ . 6 alkylOR m , -NR m R m , -NR m -C 1-4 haloalkyl, -NR m -C ⁇ . 6 alkylNR m R m , -NR m -C 1-6 alkylOR m , or -(CH 2 ) n R c ;
• R 9 is independently, at each instance, H, C ⁇ _ alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C ⁇ -4 haloalkyl, -O-d_ 6 alkylNR m R m , -O-C, -6 alkylOR m , -NR m R m , -NR m -C ⁇ _ 4 haloalkyl, -NR m -C 1-6 alkylNR m R m or -NR m -d. 6 alkylOR m ;
• Y is NH
• Z is CR 8 or N; or (D) R 1 is
• R 2 is C ⁇ _ 6 alkyl substituted by 1, 2 or 3 substituents selected from
• R 2 is -(C(R q ) 2 ) o R r , wherein R r is a saturated or unsaturated 5- or
• 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from C,.
• R 7 is C 2 - 8 alkyl, C haloalkyl, I, Br;
• R 9 is independently, at each instance, H, C ⁇ _ 9 alkyl, C ⁇ - haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C haloalkyl, -O-C ⁇ -6 alkylNR m R m , -O-C ⁇ -6 alkylOR m , -NR m R m , -NR m -d. 4 haloalkyl, -NR m -d. 6 alkylNR m R m or -NR m -C ⁇ -6 alkylOR m ;
• Y is NH; and Z is CR 8 or N; or
• R 2 is H, -OR m , Cl, C,. 3 haloalkyl or C,. 6 alkyl;
• R 4 is a saturated or unsaturated 5- or 6-membered ring containing 0, 1, 2 or
• R 9 is independently, at each instance, H, C ⁇ -9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C ⁇ -6 alkylNR m R m , -O-C ⁇ -6 alkylOR m , -NR m R m , -NR m -C ⁇ -4 haloalkyl, -NR m -C ⁇ . 6 alkylNR m R m or -NR m -C ⁇ -6 alkylOR m ;
• Y is NH
• Z is CR 8 or N.
• R 2 is H, -OR m , halo, C ⁇ -3 haloalkyl or C ⁇ -6 alkyl;
• R 4 is a saturated or unsaturated 5- or 6-membered ring containing 0, 1, 2 or 3 atoms selected from O, N and S that is optionally vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from C ⁇ -8 alkyl, C,.
• R 7 is C ⁇ . 9 alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl,
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 2, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p ;
• R is C 1-9 alkyl, C ⁇ -4 haloalkyl, halo, -O-C, -4 haloalkyl, -NR m R m or -NR m -C ⁇ . 4 haloalkyl.
• R 7 is d_ 5 alkyl, C ⁇ -4 haloalkyl, I, Br or Cl.
• R 7 is tert-butyl or trifluoromethyl.
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2 or 3 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 1, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p .
• R° is a saturated, partially-saturated or unsaturated 6-membered ring containing 0, 1, 2 or 3 N atoms, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p .
• Y is O.
• Y is NH
• R 1 is
• R 2 is H, -OR m , halo, C,. 3 haloalkyl or C ⁇ -6 alkyl;
• R is C ⁇ - alkyl, d. haloalkyl, halo, nitro, cyano, -OC ⁇ _ 6 alkyl, -O-C,. 4 haloalkyl, -O-C,. 6 alkylNR m R m , -O-C 1-6 alkylOR m , -NR m R m , -NR m -d. 4 haloalkyl, -NR m -C 1-6 alkylNR m R m or -NR m -C ]-6 alkylOR m ; [C,. 8 alkyl, C ⁇ . 5 haloalkyl, I, Br or Cl]
• R 4 is a saturated or unsaturated 5- or 6-membered ring containing 0, 1, 2 or 3 atoms selected from O, N and S that is vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from C ⁇ -8 alkyl, C ⁇ .
• R 7 is C ⁇ . alkyl, C ⁇ _ 4 haloalkyl, halo, -OC ⁇ -6 alkyl, -O-d. 4 haloalkyl, -NR m R m or -NR m -C ⁇ . 4 haloalkyl.
• R 7 is C ⁇ -5 alkyl, C ⁇ _ haloalkyl, I, Br or Cl. In another embodiment, in conjunction with the novel compound embodiments above and below, R 7 is tert-butyl or trifluoromethyl.
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2 or 3 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 1, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p .
• R° is a saturated, partially-saturated or unsaturated 6-membered ring containing 0, 1, 2 or 3 N atoms, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p .
• Y is O. In another embodiment, in conjunction with the novel compound embodiments above and below, Y is NH.
• R is
• R 2 is H, -OR m , halo, C ⁇ - 3 haloalkyl or C ⁇ . 6 alkyl;
• R 4 is not 2-aminocarbonylmethyl-2,3-dihydro-benzo[l,4]dioxin-8-yl, 2-cyanomethyl- 2,3-dihydro-benzo[l,4]dioxin-8-yl, quinolin-3-yl, 3H-quinazolin-4-on-3-yl, benzo[l,3]dioxol-5-yl, 3,3-dimethyl-l,3-dihydro-indol-2-on-6-yl or 4,4-dimethyl- 3,4-dihydro-lH-quinolin-2-on-7-yl;
• R 7 is C ⁇ -8 alkyl, C ⁇ -5 haloalkyl, I or Br;
• R 9 is H, C ⁇ -9 alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -OC ⁇ _ 6 alkyl, -O-C,. 4 haloalkyl, -O-C,. 6 alkylNR m R m , -O-C, -6 alkylOR m , -NR m R m , -NR m -C 1-4 haloalkyl, -NR m -C 1-6 alkylNR m R m or -NR m -C 1 -6 alkylOR m ; Y is NH; and
• Z is CR 8 or N.
• R 4 is a heterocycle selected from 6-indole, 7- indole, 6-3H-indole, 7-3H-indole, 6-benzo[b]furan, 7-benzo[b]furan, 6- benzothiophene, 7-benzothiophene, 6-lH-indazole, 7-lH-indazole, benzimidazole, benzthiazole, lH-benzotriazole, 7-quinoline, 8-quinoline, 7- 1,2,3,4-tetrahydroquinoline, 8-1,2,3,4-tetrahydroquinoline, isoquinolin-7-yl, isoquinolin-8-yl, 7-cinnoline, 8-cinnoline, phthalazine, 7-quinazoline, 8- quinazoline and quinoxaline, wherein the heterocycle is substituted by 0, 1, 2 or 3 substituents independently selected from
• R 9 is C ⁇ -9 alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -Od. 6 alkyl, -O-C ⁇ -4 haloalkyl, -O-d. 6 alkylNR m R m , -O-d. 6 alkylOR m , -NR m R m , -NR m -C,. 4 haloalkyl, -NR m -C 1-6 alkylNR m R m or -NR m -d. 6 alkylOR ra .
• R 9 is H.
• Z is CR 8 .
• Z is N.
• R 7 is tert-butyl or trifluoromethyl.
• R 1 is
• R 2 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 ;
• R 4 is a saturated or unsaturated 5- or 6-membered ring containing 0, 1, 2 or 3 atoms selected from O, N and S that is optionally vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from C ⁇ -8 alkyl, C 1-4 haloalky
• R 7 is C 2-8 alkyl, C ⁇ -5 haloalkyl, I, Br;
• R 9 is independently, at each instance, H, C ⁇ _ 9 alkyl, C]. 4 haloalkyl, halo, nitro, cyano, -OC]. 6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C ⁇ -6 alkylNR m R m , -O-C ⁇ . 6 alkylOR m , -NR m R m , -NR m -C,. 4 haloalkyl, -NR m -C ⁇ . 6 alkylNR m R m or
• R is -(C(R q ) 2 ) 0 phenyl, wherein the phenyl is substituted by 0, 1, 2 or 3 substituents independently selected from C].
• R 4 is a phenyl ring that is vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from C ⁇ _ 8 alkyl, d.
• R 7 is tert-butyl or trifluoromethyl.
• R 9 is H.
• Z is CR 8 .
• Z is N.
• R 1 is
• R 2 is H, -OR ra , Cl, C ⁇ . 3 haloalkyl or C 1-6 alkyl;
• R is independently, at each instance, H, C ⁇ _ 9 alkyl, C ⁇ _ haloalkyl, halo, nitro, cyano, -OC 1-6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C ]-6 alkylNR m R m , -O-C 1-6 alkylOR m , -NR m R m , -NR m -C 1-4 haloalkyl, -NR m -C ⁇ -6 alkylNR m R m or -NR m -C 1-6 alkylOR m ; Y is NH; and
• Z is CR 8 or N.
• Z is N.
• Another aspect of the invention relates to a compound having the structure:
• X is O, S or NR m ; n is independently, at each instance, 0, 1 or 2; o is independently, at each instance, 0, 1, 2 or 3;
• R m is independently at each instance H or R n ;
• R" is independently at each instance C ⁇ _ 8 alkyl, phenyl or benzyl;
• R s is R" substituted by 0, 1, 2 or 3 substituents independently selected from R q ;
• R 3 is H or C ⁇ -4 alkyl
• R 5 is H, C ⁇ _ alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C ⁇ . 4 haloalkyl, -O-C ⁇ . 6 alkylNR m R m , -O-C,. 6 alkylOR m , -NR m R m ,
• R 6 is, independently at each instance, H, C ⁇ -9 alkyl, d -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C ⁇ -6 alkylNR m R m , -O-C,. 6 alkylOR m , -NR m R m , -NR m -C ⁇ . 4 haloalkyl, -NR m -C ⁇ -6 alkylNR m R m or -NR m -C ⁇ -6 alkylOR m ;
• R 8 is H, C]. 9 alkyl, d. haloalkyl, halo, nitro, cyano, -OC ⁇ _ 6 alkyl, -O-d. 4 haloalkyl, -O-C ⁇ -6 alkylNR m R m , -O-C ⁇ . 6 alkylOR m , -NR m R m , -NR m -C ⁇ -4 haloalkyl, -NR m -C,. 6 alkylNR m R m or -NR m -C 1 . 6 alkylOR m ; and (A) R 1 is
• R 2 is H, -OR m , halo, C,. 3 haloalkyl or C ⁇ -6 alkyl;
• R 7 is C 1-9 alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -OC ⁇ . 6 alkyl, -O-C 1-4 haloalkyl, -O-C,. 6 alkylNR m R m , -O-C ⁇ . 6 alkylOR m , -NR m R m , -NR m -C haloalkyl, -NR m -C,. 6 alkylNR m R m or -NR m -C,. 6 alkylOR m ;
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 2, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p ;
• Y is O or NH
• R >2 ⁇ ; is H, -OR , halo, C 1-3 haloalkyl or C 1-6 alkyl;
• R 7 is C]. 9 alkyl, C ⁇ . 4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C,. 4 haloalkyl, -O-C 1-6 alkylNR m R m , -O-C,. 6 alkylOR m , -NR m R m , -NR m -C,. 4 haloalkyl, -NR m -C ⁇ . 6 alkylNR m R m or -NR m -C ⁇ . 6 alkylOR m ;
• R 2 is H, -OR m , halo, C ⁇ -3 haloalkyl or C ⁇ -6 alkyl;
• R 4 is not 2-aminocarbonylmethyl-2,3-dihydro-benzo[l,4]dioxin-8-yl, 2-cyanomethyl- 2,3-dihydro-benzo[l,4]dioxin-8-yl, quinolin-3-yl, 3H-quinazolin-4-on-3-yl, benzo[l,3]dioxol-5-yl, 3,3-dimethyl-l,3-dihydro-indol-2-on-6-yl or 4,4-dimethyl- 3,4-dihydro-lH-quinolin-2-on-7-yl;
• R 7 is C ⁇ . 8 alkyl, C ⁇ . 5 haloalkyl, I or Br R 9 is H, C ⁇ _ 9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC].
• R 9 is independently, at each instance, H, C ⁇ -9 alkyl, d. 4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C,. 6 alkylNR m R m , -O-d. 6 alkylOR m , -NR m R m , -NR m -C 1-4 haloalkyl, -NR m -C,. 6 alkylNR m R m or -NR m -C,. 6 alkylOR m ; Y is NH; and Z is CR 8 or N; or (D) R 1 is
• R 2 is -(C(R q ) 2 ) 0 ⁇ henyl, wherein the phenyl is substituted by 0, 1, 2 or 3 substituents independently selected from d.
• R 7 is C 2 . 8 alkyl, C ⁇ . 5 haloalkyl, I, Br;
• R 9 is independently, at each instance, H, C ⁇ -9 alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -OC,. 6 alkyl, -O-C 1-4 haloalkyl, -O-C ⁇ -6 alkylNR m R m ,
• Y is NH
• Z is CR 8 or N; or (E) R 1 is
• R 2 is H, -OR m , Cl, C,. 3 haloalkyl or C,. 6 alkyl;
• R 9 is independently, at each instance, H, C]. alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C ⁇ . 6 alkylNR m R m , -O-C,. 6 alkylOR m , -NR m R m , -NR m -C, -4 haloalkyl, -NR m -C ⁇ . 6 alkylNR m R m or -NR m -C,. 6 alkylOR m ; Y is NH; and
• Z is CR 8 or N.
• R 1 is
• R 2 is H, -OR m , halo, C,. 3 haloalkyl or C ⁇ -6 alkyl;
• R 4 is a saturated or unsaturated 5- or 6-membered ring containing 0, 1, 2 or
• R 7 is C ⁇ -9 alkyl, C ⁇ _ 4 haloalkyl, halo, nitro, cyano, -Od -6 alkyl, -O-C ⁇ -4 haloalkyl, -O-C,. 6 alkylNR m R m , -O-C ⁇ - 6 alkylOR m , -NR m R m , -NR m -C 1-4 haloalkyl, -NR m -C ⁇ -6 alkylNR m R m or -NR m -C,. 6 alkylOR m ;
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 2, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p ; R p is independently at each instance C ⁇ -8 alkyl, C ⁇ .
• Y is O or NH.
• R 4 is a phenyl ring that is vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from C ⁇ -8 alkyl, d.
• R 7 is C ⁇ _ alkyl, C ⁇ -4 haloalkyl, halo, -OC ⁇ _ 6 alky], -O-C 1-4 haloalkyl, -NR m R m or -NR m -C ⁇ -4 haloalkyl.
• R 7 is C ⁇ -5 alkyl, C ⁇ _ 4 haloalkyl, I, Br or Cl. In another embodiment, in conjunction with the novel compound embodiments above and below, R 7 is tert-butyl or trifluoromethyl.
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2 or 3 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 1, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p .
• R° is a saturated, partially-saturated or unsaturated 6-membered ring containing 0, 1, 2 or 3 N atoms, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p .
• Y is O.
• Y is NH
• R 1 is
• R 2 is H, -OR m , halo, C, -3 haloalkyl or C ⁇ alkyl;
• R 7 is C ⁇ -9 alkyl, C ⁇ - haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C,. 4 haloalkyl, -O-C 1-6 alkylNR m R m , -O-C,. 6 alkylOR m , -NR m R m ,
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic or 7-, 8-, 9-, 10- or 11-membered bicyclic ring containing 0, 1, 2, 3 or 4 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 2, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p ;
• Y is O or NH.
• R is a phenyl ring that is vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from d. 8 alkyl, C,.
• R 7 is C ⁇ -9 alkyl, C ⁇ _ haloalkyl, halo, -OC ⁇ _ 6 alkyl, -O-C,. 4 haloalkyl, -NR m R m or -NR m -C,. haloalkyl.
• R 7 is C ⁇ -5 alkyl, C ⁇ -4 haloalkyl, I, Br or Cl. In another embodiment, in conjunction with the novel compound embodiments above and below, R 7 is tert-butyl or trifluoromethyl.
• R° is a saturated, partially-saturated or unsaturated 5-, 6- or 7-membered monocyclic ring containing 0, 1, 2 or 3 atoms selected from N, O and S, so long as the combination of O and S atoms is not greater than 1, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p .
• R° is a saturated, partially-saturated or unsaturated 6-membered ring containing 0, 1, 2 or 3 N atoms, wherein the carbon atoms of the ring are substituted by 0, 1 or 2 oxo groups, wherein the ring is substituted by 0, 1, 2 or 3 substituents independently selected from R p .
• Y is O.
• Y is NH
• R 1 is
• R 2 is H, -OR m , halo, C ⁇ -3 haloalkyl or C ⁇ -6 alkyl;
• R 4 is not 2-aminocarbonylmethyl-2,3-dihydro-benzo[l,4]dioxin-8-yl, 2-cyanomethyl- 2,3-dihydro-benzo[l,4]dioxin-8-yl, quinolin-3-yl, 3H-quinazolin-4-on-3-yl, benzo[l,3]dioxol-5-yl, 3,3-dimethyl-l,3-dihydro-indol-2-on-6-yl or 4,4-dimethyl- 3,4-dihydro-lH-quinolin-2-on-7-yl;
• R 7 is C ⁇ . 8 alkyl, Ci.shaloalkyl, I or Br;
• R 9 is H, C ⁇ -9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C,. 4 haloalkyl, -O-C ⁇ -6 alkylNR m R m , -O-C 1-6 alkylOR m , -NR m R m ,
• R 4 is a heterocycle selected from 6-indole, 7- indole, 6-3H-indole, 7-3H-indole, 6-benzo[b] furan, 7-benzo[b]furan, 6- benzothiophene, 7-benzothiophene, 6-lH-indazole, 7-lH-indazole, benzimidazole, benzthiazole, lH-benzotriazole, 7-quinoline, 8-quinoline, 7- 1,2,3,4-tetrahydroquinoline, 8-1,2,3,4-tetrahydroquinoline, isoquinolin-7-yl, isoquinolin-8-yl, 7-cinnoline, 8-cinnoline, phthalazine, 7-quinazoline, 8- quinazoline and quinoxaline, wherein the heterocycle is substituted by 0, 1, 2 or 3 substituents independently selected from
• R 9 is C ⁇ -9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C,. 4 haloalkyl, -O-C ⁇ . 6 alkylNR m R m , -O-d. 6 alkylOR m , -NR m R m , -NR m -C 1-4 haloalkyl, -NR m -C,. 6 alkylNR m R m or -NR m -C,. 6 alkylOR m .
• R is H.
• Z is CR 8 .
• Z is N.
• R 7 is tert-butyl or trifluoromethyl.
• R 1 is
• R 2 is a saturated or unsaturated 5- or 6-membered ring heterocycle containing 1, 2 or 3 heteroatoms independently selected from N, O and S, wherein no more than 2 of the ring members are O or S, wherein the heterocycle is optionally fused with a phenyl ring, and the heterocycle or fused phenyl ring is substituted by 0, 1, 2 or 3 substituents independently selected from R 5 , R 6 and R 7 ;
• R 4 is a saturated or unsaturated 5- or 6-membered ring containing 0, 1, 2 or 3 atoms selected from O, N and S that is optionally vicinally fused with a saturated or unsaturated 3- or 4-atom bridge containing 0, 1, 2 or 3 atoms selected from O, N and S with the remaining atoms being carbon, so long as the combination of O and S atoms is not greater than 2, wherein the ring and bridge are substituted by 0, 1, 2 or 3 substituents independently selected from C 1-8 alkyl, C, -4 haloalky
• R 7 is C 2 . 8 alkyl, C ⁇ - 5 haloalkyl, I, Br;
• R 9 is independently, at each instance, H, C ⁇ _ 9 alkyl, C ⁇ -4 haloalkyl, halo, nitro, cyano, -OC ⁇ -6 alkyl, -O-C haloalkyl, -O-C ⁇ . 6 alkylNR m R m ,
• Y is NH
• Z is CR 8 or N.
• R 2 is -(C(R q ) 2 ) 0 phenyl, wherein the phenyl is substituted by 0, 1, 2 or 3 substituents independently selected from C ⁇ -8 alkyl, d.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Dermatology (AREA)
• Pulmonology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Pain & Pain Management (AREA)
• Diabetes (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Rheumatology (AREA)
• Endocrinology (AREA)
• Obesity (AREA)
• Ophthalmology & Optometry (AREA)
• Hematology (AREA)
• Emergency Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Otolaryngology (AREA)
• Virology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Furan Compounds (AREA)

Priority Applications (5)

Applications Claiming Priority (8)

Publications (3)

Family

ID=27502596

Family Applications (1)

Country Status (8)

Cited By (69)

Families Citing this family (63)

Family Cites Families (42)

• 2002
  • 2002-12-10 MX MXPA04005427A patent/MXPA04005427A/es active IP Right Grant
  • 2002-12-10 PL PL02373484A patent/PL373484A1/xx unknown
  • 2002-12-10 EP EP02799927A patent/EP1463714A4/en not_active Withdrawn
  • 2002-12-10 CA CA002468544A patent/CA2468544A1/en not_active Abandoned
  • 2002-12-10 WO PCT/US2002/039589 patent/WO2003049702A2/en not_active Ceased
  • 2002-12-10 US US10/316,295 patent/US7582657B2/en not_active Expired - Fee Related
  • 2002-12-10 AU AU2002364549A patent/AU2002364549B2/en not_active Ceased
  • 2002-12-10 JP JP2003550753A patent/JP2005518371A/ja active Pending
• 2005
  • 2005-04-05 US US11/099,978 patent/US20050272931A1/en not_active Abandoned
  • 2005-04-05 US US11/100,077 patent/US7579347B2/en not_active Expired - Fee Related
  • 2005-04-05 US US11/100,272 patent/US20060030618A1/en not_active Abandoned
• 2009
  • 2009-06-26 US US12/492,376 patent/US20090264424A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events